Probucol treatment decreases serum concentrations of diet-derived antioxidants.

  title={Probucol treatment decreases serum concentrations of diet-derived antioxidants.},
  author={Liselotte Sch{\"a}fer Elinder and Karin H{\aa}dell and Jan Johansson and J{\o}rgen M{\o}lgaard and Ingar Morten K Holme and Anders G. Olsson and G{\"o}ran Walldius},
  journal={Arteriosclerosis, thrombosis, and vascular biology},
  volume={15 8},
The effect of probucol, which is both a cholesterol-lowering drug and an antioxidant, on the serum concentrations of diet-derived antioxidants vitamin E, beta-carotene, lycopene, and vitamin A was studied in 303 hypercholesterolemic subjects. In a 3-year, double-blind, randomized trial we investigated to determine whether combined treatment with diet, cholestyramine, and probucol could reduce the progression of femoral atherosclerosis. Serum and lipoprotein antioxidant levels were measured by… 

Effect of probucol on LDL oxidation and atherosclerosis in LDL receptor-deficient mice.

Probucol not only failed to decrease but actively increased atherogenesis in LDLR-/- mice in a dose-dependent manner, even though it provided a very strong antioxidant protection of LDL.

Lowering of HDL2b by probucol partly explains the failure of the drug to affect femoral atherosclerosis in subjects with hypercholesterolemia. A Probucol Quantitative Regression Swedish Trial (PQRST) Report.

The correlation between drug-induced change in the relative HDL2b concentration and change in atherosclerosis was independent of the alteration in triglyceride concentration and could not be explained by treatment interaction.


High levels of monounsaturated fat in the diet do not appear to increase lycopene absorption and serum levels compared to very low fat diet, and there was a better serum lipid profile after MUFA diet compared to HCLF diet.

Efficacy and safety of plant stanols and sterols in the management of blood cholesterol levels.

Present evidence is sufficient to promote use of sterols and stanols for lowering LDL cholesterol levels in persons at increased risk for coronary heart disease.

Increase of vitamin E content in LDL and reduction of atherosclerosis in cholesterol-fed rabbits by a water-soluble antioxidant-rich fraction of Salvia miltiorrhiza.

It is concluded that the reduction of atherosclerosis by SM relies not only on its cholesterol-lowering effect but more heavily on its antioxidant potential to prevent endothelial damage and inhibit LDL oxidative modification in hypercholesterolemic animals.

Effects of diets enriched with two different plant stanol ester mixtures on plasma ubiquinol-10 and fat-soluble antioxidant concentrations.

It is concluded that the increase in endogenous cholesterol synthesis during plant stanol ester consumption does not result in increased LDL-cholesterol-standardized concentrations of ubiquinol-10, a side product of the cholesterol synthesis cascade and of those fat-soluble antioxidants that are mainly carried by LDL.

Probucol induces the generation of lipid peroxidation products in erythrocytes and plasma of male cynomolgus macaques

Probucol-induced disruption of redox homeostasis in erythrocytes could be effective in the inhibition of parasite proliferation and the potential for the clinical application of probucol as an anti-malarial therapy is verified.

Protective effects of carvedilol, a vasodilating beta-adrenoceptor blocker, against in vivo low density lipoprotein oxidation in essential hypertension.

The antihypertensive and antioxidant effects of carvedilol, a new vasodilating beta-adrenoceptor blocking agent in a group of patients with mild to moderate essential hypertension after 4-month treatment markedly increased the resistance to oxidation of LDL isolated from treated patients and reduced the extent of in vivo LDL oxidation.



Effect of probucol dosage on plasma lipid and lipoprotein levels and on protection of low density lipoprotein against in vitro oxidation in humans.

Probucol levels in plasma LDL rose less rapidly in the 1-tablet group but were nearly 50% of levels in the 4- tablet group after 6 months of therapy, and the decrease in LDL susceptibility to copper or endothelial cell-mediated oxidative modification was correlated with the content of probucol in LDL.

Probucol reduces plasma lipid peroxides in man.

Distribution of orally administered beta-carotene among lipoproteins in healthy men.

Intestinal input accounts for early rises in circulating BC concentrations whereas hepatic secretion is the source of later increases, and transfer of BC may occur among all of the lipoproteins.

Simultaneous measurement of serum probucol and lipid-soluble antioxidants.

In order to attain a reproducible recovery of particularly the carotenes, the total lipid content of the samples had to be controlled by dilution of the sample before extraction by using a microbore column and by monitoring the effluent at the optimum wavelengths of each substance with a diode array detector.

The effect of cholestyramine on intestinal absorption.

There has been a significant decrease in the mean serum concentrations of vitamins A and E and of inorganic phosphorus over the first two years of treatment, although values remain within the normal range.

In vitro studies on the distribution of probucol among human plasma lipoproteins.

Investigation in in vitro studies of the role of human plasma lipoproteins as carriers in the blood transport of the cholesterol-lowering and water-insoluble drug, probucol, found that they account for a negligible part in the interaction of Probucol with blood components.